Pictor receives CE Mark for COVID-19 test

By LabPulse.com staff writers

June 23, 2022 -- Pictor has received Europe's CE Mark for its PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test.

The PictArray SARS-CoV-2 assay is the first test of its kind, according to the company. The test enables personalized COVID-19 assessments by detecting if a patient has antibodies from a previous infection of SARS-CoV-2 (from spike protein and nucleocapsid protein antibodies) or from vaccination alone (SP antibodies only).

In addition, the test also indicates whether at-risk patients have failed to mount a detectable antibody response, despite vaccination or infection (SP- and NP-negative), Pictor said.

The CE Mark allows the company to market its COVID-19 antibody test in Europe and seek regulatory approval in Southeast Asia.

Pictor, Mobility Health partner on new SARS-CoV-2 test
Biotechnology firm Pictor is partnering with Mobility Health on a new SARS-CoV-2 assay that can differentiate between previous infection and vaccination...

Copyright © 2022 LabPulse.com

Last Updated mp 6/23/2022 12:23:46 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current